Drug Trial Radar · NCT02255552
Study of Eteplirsen in DMD Patients
Last checked: Nov 20, 2026Latest source record: Jan 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
109
Actual
Start
Nov 17, 2014
Primary completion
Jun 14, 2019
Study completion Jun 14, 2019
Sponsor
- Lead sponsor
- Sarepta Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 2, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 7 years, up to 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this study is to provide evidence of efficacy of eteplirsen (AVI-4658) in Duchenne muscular dystrophy (DMD) patients that are amenable to skipping exon 51. Additional objectives include evaluation of safety, biomarkers and the long-term effects of eteplirsen up to 96 weeks, followed by a safety extension (not to exceed 48 weeks).
Conditions
- Duchenne Muscular Dystrophy (DMD)
Interventions
eteplirsenDrug
Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks, followed by a safety extension (not to exceed 48 weeks).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the 6 Minute Walk Test (6MWT) Distance at Week 96Time frame: Baseline, Week 96
Locations
37 sites in 1 country. Site status is shown where the registry gives one.
Neuromuscular Research Center
Phoenix, Arizona
David Geffen School of Medicine at UCLA
Los Angeles, California
University of California, Davis Medical Center
Sacramento, California
Rady Children's Hospital, U.C. San Diego
San Diego, California
Stanford University School of Medicine/Medical Center
Stanford, California
Children's Hospital Colorado
Aurora, Colorado
Connecticut Children's Medical Center
Hartford, Connecticut
Children's National Health System
Washington D.C., District of Columbia
The University of Florida, Powell Gene Therapy Center
Gainesville, Florida
NW FL Clinical Research Group, LLC
Gulf Breeze, Florida
Nemours Children's Hospital
Orlando, Florida
Rare Disease Research Center
Atlanta, Georgia
Emory University
Atlanta, Georgia
Ann and Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
University of Iowa Children's Hospital
Iowa City, Iowa
University of Kansas Medical Center
Kansas City, Kansas
Kennedy Krieger Institute
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Children's Hospital Boston
Boston, Massachusetts
Children's Hospital of Michigan
Detroit, Michigan
University of Minnesota
Minneapolis, Minnesota
St. Louis Children's Hospital
St Louis, Missouri
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire
Columbia University Medical Center
New York, New York
University of Rochester Clinical Research Center
Rochester, New York
Levine Childrens Hospital, Carolinas Medical Center
Charlotte, North Carolina
Cincinnati Children's Hospital Medical Center (CCHMC)
Cincinnati, Ohio
Nationwide Children's Hospital
Columbus, Ohio
Shriners Hospital for Children
Portland, Oregon
Penn State Hershey Medical Center
Hershey, Pennsylvania
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
The University of Texas Southwestern Medical Center
Dallas, Texas
Texas Children's Hospital
Houston, Texas
University of Utah
Salt Lake City, Utah
Seattle Children's Hospital
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.